 |
|
| The pharmaceutical team develops new pharmaceutical products through formulation research of new compounds,existing drugs and physiologically active Herbal extracts, and drug delivery systems(DDS). |
|
 |
|
 |
 |
 |
Formulation of the 3rd generation platinum complex anticancer drug following Cisplatin and Carboplatin.
with Low Side Effects Manifested and High Safety and Efficiency |
|
|
 |
 |
| Formulation of effective components which are extracted from the green ginkgo biloba leaves by the use of patented technology |
|
|
 |
 |
Formulation of herbal extracts from Clematis mandshurica, Trichosanthes kirilowii, Prunella vulgaris Joins tab. inhibits the degradation of proteoglycan and attenuates the osteoarthritis-like change induced by collagenase and free radical.
So, Joins tab. exerts prophylactic effect against the progress of osteoarthritis. Joins tab. has lower adverse effects than the existing NSAIDs, so it can be prescribed to old patients for a long time.
Through the Chalmers & Dale Co , it has been exported to the Australia and the Newzeland. |
|
|
 |
 |
Acid-unstable omeprazole was successfully formulated in the form of tablet, using world-patented Cyclodextrin Inclusion technology .
Acknowledging the Omeprazole stabilization technology as a patent technology, Omed tab has exported to Germany through the Stada.
Omed® is the first drug that passed the inspection of the German government authorities among the finished medicine produced in Korea.
In 2003, through multinational marketing company we are trying to launch OMED tab in US market. |
|
|
 |
 |
| It is the first patch formulation in the world to exhibit both anti-inflammatory and analgesic actions..It has observable potent therapeutic efficacy without any systemic side effects since the active ingredient is delivered locally and directly from the patch to the lesion via the skin layer. It's Market share in Korea is the first in transdermal patch . Through the marketing company, Macromed we are exporting it to the Philippines since 2002 |
|
|
|
 |
Currently, based on knowledge accumulated from research on the transdermal drug delivery system, efforts are being made to develop non-steroidal anti-inflammatory analgesics and develop a new formulation of analgesia.
Furthermore, based on the accumulation of related technologies, development of a new formulation such as a controlled release system is being developed. |
|
|
|
|
 |
